Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Blood ; 121(10): 1850-7, 2013 Mar 07.
Artigo em Inglês | MEDLINE | ID: mdl-23303820

RESUMO

Scott syndrome, a bleeding disorder caused by defective phospholipid scrambling, has been associated with mutations in the TMEM16F gene. The role of TMEM16F in apoptosis- or agonist-induced phosphatidylserine (PS) exposure was studied in platelets from a Scott syndrome patient and control subjects. Whereas stimulation of control platelets with the BH3-mimetic ABT737 resulted in 2 distinct fractions with moderate and high PS exposure, the high PS-exposing fraction was markedly delayed in Scott platelets. High, but not moderate, PS exposure in platelets was suppressed by chelation of intracellular Ca(2+), whereas caspase inhibition completely abolished ABT737-induced PS exposure in both Scott and control platelets. On the other hand, high PS exposure induced by the Ca(2+)-mobilizing agonists convulxin/thrombin fully relied on mitochondrial depolarization and was virtually absent in Scott platelets. Finally, PS exposure induced by collagen/thrombin was partly affected in Scott platelets, and the residual PS positive fraction was insensitive to inhibition of caspases or mitochondrial depolarization. In conclusion, TMEM16F is not required for, but enhances, caspase-dependent PS exposure; convulxin-/thrombin-induced PS exposure is entirely dependent on TMEM16F, whereas collagen/thrombin-induced PS exposure results from 2 distinct pathways, one of which involves mitochondrial depolarization and is mediated by TMEM16F.


Assuntos
Apoptose , Transtornos da Coagulação Sanguínea/patologia , Plaquetas/patologia , Cálcio/metabolismo , Fosfatidilserinas/metabolismo , Proteínas de Transferência de Fosfolipídeos/metabolismo , Ativação Plaquetária , Anoctaminas , Transtornos da Coagulação Sanguínea/metabolismo , Plaquetas/metabolismo , Estudos de Casos e Controles , Caspases/metabolismo , Venenos de Crotalídeos/farmacologia , Ciclofilinas/metabolismo , Citometria de Fluxo , Hemostáticos/farmacologia , Humanos , Lectinas Tipo C , Mitocôndrias/efeitos dos fármacos , Mitocôndrias/metabolismo , Trombina/farmacologia
2.
Eur J Pharmacol ; 693(1-3): 1-6, 2012 Oct 15.
Artigo em Inglês | MEDLINE | ID: mdl-22959357

RESUMO

Ribavirin in combination with interferon-α is the standard treatment for chronic hepatitis C, but often induces severe anemia forcing discontinuation of the therapy. Whereas suppression of bone marrow by interferon may impact on the production of erythrocytes, it has been suggested that accumulation of ribavirin in erythrocytes induces alterations causing an early removal of these cells by the mononuclear phagocytic system. Externalization of phosphatidylserine, which is exclusively present in the cytoplasmic leaflet of the plasma membrane, is a recognition signal for phagocytosis in particular of apoptotic cells. Here, we demonstrate that surface exposure of phosphatidylserine upon prolonged treatment of erythrocytes with ribavirin results mainly from inactivation of the aminophospholipid translocase, an ATP-dependent lipid pump, which specifically transports phosphatidylserine from the outer to the inner leaflet of the plasma membrane. Inactivation is due to severe ATP depletion, although competitive inhibition by ribavirin or its phosphorylated derivatives cannot be excluded. Phospholipid scramblase, responsible for collapse of lipid asymmetry, appears to be of minor importance as erythrocytes of patients with the Scott syndrome, lacking Ca(2+)-induced lipid scrambling, are equally sensitive to ribavirin treatment. Neither the antioxidant N-acetylcysteine nor the pan-caspase inhibitor Q-VD-OPH did affect ribavirin-induced phosphatidylserine exposure, suggesting that oxidative stress or apoptotic-related mechanisms are not involved in this process. In conclusion, we propose that spontaneous loss of lipid asymmetry, not corrected by aminophospholipid translocase activity, is the mechanism for ribavirin-induced phosphatidylserine exposure that may contribute to ribavirin-induced anemia.


Assuntos
Antivirais/farmacologia , Eritrócitos/efeitos dos fármacos , Ionomicina/farmacologia , Fosfatidilserinas/metabolismo , Proteínas de Transferência de Fosfolipídeos/antagonistas & inibidores , Ribavirina/farmacologia , Trifosfato de Adenosina/metabolismo , Células Cultivadas , Eritrócitos/metabolismo , Hemólise/efeitos dos fármacos , Humanos , Proteínas de Transferência de Fosfolipídeos/metabolismo
3.
Blood Coagul Fibrinolysis ; 18(7): 627-36, 2007 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-17890950

RESUMO

Recent human studies reveal that hyperglycemia induces procoagulant and antifibrinolytic effects in blood that may contribute to a greater risk of arterial thrombosis, but the direct relationship between high blood glucose levels and thrombosis has not yet been investigated. We performed a number of experiments to clarify whether hyperglycemia was causally related to arterial thrombosis and whether the combined stimulus of hyperglycemia and inflammation would enhance the thrombotic effect. In a model of ferric-chloride-induced carotid artery thrombosis, hyperglycemia did not influence the time to occlusion in mice pretreated with streptozotocin, but the rate of thrombus formation was accelerated. This effect was associated with increased thrombin generation and could not be explained by changes in vessel-wall tissue factor activity. The prothrombotic effect of hyperglycemia was assessed in a separate experiment, showing that collagen/thrombin-induced platelet procoagulant activity was increased in hyperglycemic mice. The effect of inflammation was studied by injecting a low dose of endotoxin that caused a systemic inflammatory state after 24 h (increased plasma levels of tumor necrosis factor alpha, interleukin-6 and monocyte chemotactic protein 1 in diabetic and nondiabetic mice) associated with a mild delay in thrombus formation. This reduced rate of thrombus formation was attenuated by hyperglycemia. Together, these data establish a discrete but clear contribution of hyperglycemia in experimental arterial thrombosis.


Assuntos
Trombose das Artérias Carótidas/fisiopatologia , Endotoxinas/sangue , Fibrinolíticos/sangue , Hiperglicemia/fisiopatologia , Animais , Coagulação Sanguínea/efeitos dos fármacos , Trombose das Artérias Carótidas/induzido quimicamente , Trombose das Artérias Carótidas/prevenção & controle , Cloretos , Diabetes Mellitus Experimental/sangue , Diabetes Mellitus Experimental/induzido quimicamente , Diabetes Mellitus Experimental/fisiopatologia , Modelos Animais de Doenças , Endotoxinas/farmacologia , Feminino , Compostos Férricos , Fibrinolíticos/farmacologia , Hiperglicemia/sangue , Hiperglicemia/induzido quimicamente , Camundongos , Camundongos Endogâmicos C57BL , Estreptozocina , Trombina/efeitos dos fármacos , Tempo de Trombina/métodos , Tromboflebite/tratamento farmacológico , Tromboflebite/metabolismo
4.
Blood ; 108(7): 2223-8, 2006 Oct 01.
Artigo em Inglês | MEDLINE | ID: mdl-16741254

RESUMO

The platelet procoagulant response requires a sustained elevation of the intracellular Ca2+ concentration, [Ca2+]i, causing exposure of phosphatidylserine (PS) at the outer surface of the plasma membrane. An increased [Ca2+]i also activates Ca2+-dependent K+ channels. Here, we investigated the contribution of the efflux of K+ ions on the platelet procoagulant response in collagen-thrombin-activated platelets using selective K+ channel blockers. The Gardos channel blockers clotrimazol, charybdotoxin, and quinine caused a similar decrease in prothrombinase activity as well as in the number of PS-exposing platelets detected by fluorescence-conjugated annexin A5. Apamin and iberiotoxin, inhibitors of other K+ channels, were without effect. Only clotrimazol showed a significant inhibition of the collagen-plus-thrombin-induced intracellular calcium response. Clotrimazol and charybdotoxin did not inhibit aggregation and release under the conditions used. Inhibition by Gardos channel blockers was reversed by valinomycin, a selective K+ ionophore. The impaired procoagulant response of platelets from a patient with Scott syndrome was partially restored by pretreatment with valinomycin, suggesting a possible defect of the Gardos channel in this syndrome. Collectively, these results provide evidence for the involvement of efflux of K+ ions through Ca2+-activated K+ channels in the procoagulant response of platelets, opening potential strategies for therapeutic interventions.


Assuntos
Fatores de Coagulação Sanguínea/metabolismo , Plaquetas/metabolismo , Anexina A5/química , Apamina/farmacologia , Cálcio/metabolismo , Membrana Celular/metabolismo , Charibdotoxina/farmacologia , Clotrimazol/farmacologia , Humanos , Ionóforos/farmacologia , Peptídeos/farmacologia , Fosfatidilserinas/química , Potássio/química , Tromboplastina/metabolismo , Valinomicina/farmacologia
5.
Mol Membr Biol ; 20(1): 83-91, 2003.
Artigo em Inglês | MEDLINE | ID: mdl-12745928

RESUMO

Membrane-perturbing agents that cause transformation of biconcave erythrocytes into echinocytes or stomatocytes were used to investigate the influence of erythrocyte shape on the rate of Ca(2+)-induced scrambling of phospholipids. Erythrocytes were treated with a variety of lipid-soluble compounds to induce these shape changes, followed by incubation with calcium and ionomycin to activate lipid scramblase. Prothrombinase activity of the cells was used to monitor the rate of surface exposure of phosphatidylserine, which is taken as a measure of scramblase activity. Echinocytes show an enhanced rate of scrambling, whereas stomatocytes show a reduced rate, relative to normocytes. This phenomenon appears to correlate with enhanced and diminished micro-exovesicle shedding from echinocytes and stomatocytes, respectively. It is concluded that the rate of calcium-induced phosphatidylserine exposure (rate of lipid scrambling) in erythrocytes depends for a considerable part on the cells' ability to form microvesicles.


Assuntos
4-Cloro-7-nitrobenzofurazano/análogos & derivados , Cálcio/metabolismo , Eritrócitos/citologia , Eritrócitos/metabolismo , Fosfatidilserinas/metabolismo , Proteínas de Transferência de Fosfolipídeos , 4-Cloro-7-nitrobenzofurazano/farmacologia , Cálcio/farmacologia , Proteínas de Transporte/efeitos dos fármacos , Proteínas de Transporte/metabolismo , Tamanho Celular/efeitos dos fármacos , Células Cultivadas , Clorpromazina/farmacologia , Detergentes/farmacologia , Dibucaína/farmacologia , Eritrócitos/efeitos dos fármacos , Humanos , Ionóforos/farmacologia , Lidocaína/farmacologia , Proteínas de Membrana/efeitos dos fármacos , Proteínas de Membrana/metabolismo , Fosfatidilcolinas/farmacologia , Vesículas Secretórias/metabolismo , Tromboplastina/efeitos dos fármacos , Tromboplastina/metabolismo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...